ubet63 free 100 download
Baurs leadership team honoured at ‘Global CEO Forum’WASHINGTON NASA’s Parker Solar Probe survived its record-breaking closest approach to the solar surface on Dec. 24, the US space agency said on Friday. By flying 3.8 million miles (6.1 million kilometers) above the surface of the Sun, it broke its previous record, according to the US space agency. "Flying this close to the Sun is a historic moment in humanity’s first mission to a star," Nicky Fox, leader of NASA’s science mission directorate, said in a statement. "By studying the Sun up close, we can better understand its impacts throughout our solar system, including on the technology we use daily on Earth and in space, as well as learn about the workings of stars across the universe to aid in our search for habitable worlds beyond our home planet," Fox added. Launched in 2018, the spacecraft used seven flybys of Venus to gravitationally direct it ever closer to the Sun.WASHINGTON: A senior White House official on Thursday said nuclear-armed Pakistan is developing long-range ballistic missile capabilities that eventually could allow it to strike targets outside of South Asia, including in the United States. In his stunning revelation about the onetime close U.S. partner, Deputy National Security Advisor Jon Finer said Islamabad's conduct raised "real questions" about the aims of its ballistic missile program. "Candidly, it's hard for us to see Pakistan's actions as anything other than an emerging threat to the United States," Finer told the Carnegie Endowment for International Peace audience. Pakistan terms US sanctions on entities as unfortunate, biased "Pakistan has developed increasingly sophisticated missile technology, from long-range ballistic missile systems to equipment that would enable the testing of significantly larger rocket motors," he said. If those trends continue, Finer said, "Pakistan will have the capability to strike targets well beyond South Asia, including in the United States." His speech came a day after Washington announced a new roundof sanctions related to Pakistan's ballistic missile developmentprogram, including on the state-run defense agency that oversees the program.
Vikings withstand Bears' furious rally, win on field goal in OT
None
NoneVictory Capital Management Inc. bought a new stake in Astrana Health, Inc. ( NASDAQ:ASTH – Free Report ) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 44,806 shares of the company’s stock, valued at approximately $2,596,000. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in Astrana Health in the third quarter valued at $34,000. Nisa Investment Advisors LLC acquired a new position in Astrana Health in the third quarter valued at $35,000. Central Pacific Bank Trust Division acquired a new position in Astrana Health in the third quarter valued at $160,000. Everence Capital Management Inc. acquired a new position in Astrana Health in the third quarter valued at $272,000. Finally, Granite Bay Wealth Management LLC acquired a new position in Astrana Health in the third quarter valued at $290,000. Institutional investors and hedge funds own 52.77% of the company’s stock. Astrana Health Stock Performance NASDAQ:ASTH opened at $42.11 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health, Inc. has a one year low of $32.32 and a one year high of $63.20. The business’s 50-day simple moving average is $54.17 and its 200 day simple moving average is $47.80. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 32.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.24. Wall Street Analyst Weigh In A number of brokerages recently weighed in on ASTH. Robert W. Baird lifted their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. KeyCorp initiated coverage on Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Truist Financial boosted their price objective on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus boosted their price objective on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, BTIG Research boosted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $65.17. Get Our Latest Stock Report on ASTH About Astrana Health ( Free Report ) Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. Further Reading Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. ( NASDAQ:ASTH – Free Report ). Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter .
Godaddy CEO Amanpal Singh Bhutani sells $1.9 million in stock
Monsanto added six rebounds for the Roadrunners (6-5). Sky Wicks scored 20 points while shooting 8 for 12, including 4 for 7 from beyond the arc and added eight rebounds and three steals. Amir "Primo" Spears shot 5 of 10 from the field, including 1 for 5 from 3-point range, and went 5 for 6 from the line to finish with 16 points. Domonique Wilkins and Orlando Gooden each scored 19 points for Southwestern Adventist. Jason Garcia had 13 points, four assists and two steals. Monsanto led his team in scoring with 16 points in the first half to help put them up 61-24 at the break. UTSA extended its lead to 87-38 during the second half, fueled by a 13-3 scoring run. Wicks scored a team-high 10 points in the second half. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Mutual of America Capital Management LLC acquired a new stake in Parsons Co. ( NYSE:PSN – Free Report ) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,250 shares of the company’s stock, valued at approximately $2,618,000. Other hedge funds also recently made changes to their positions in the company. V Square Quantitative Management LLC acquired a new stake in Parsons during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Parsons during the third quarter valued at about $45,000. Tanglewood Legacy Advisors LLC purchased a new stake in shares of Parsons during the second quarter worth about $44,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Parsons in the third quarter worth about $72,000. Finally, Blue Trust Inc. boosted its holdings in Parsons by 23.6% in the second quarter. Blue Trust Inc. now owns 1,041 shares of the company’s stock valued at $86,000 after purchasing an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 98.02% of the company’s stock. Analyst Ratings Changes PSN has been the topic of a number of recent analyst reports. Truist Financial cut their target price on Parsons from $130.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday. KeyCorp increased their price objective on shares of Parsons from $116.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Raymond James downgraded shares of Parsons from a “strong-buy” rating to an “outperform” rating and set a $115.00 target price for the company. in a research report on Wednesday, October 23rd. Robert W. Baird lifted their price target on Parsons from $103.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Benchmark upped their price objective on Parsons from $68.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Parsons currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.13. Parsons Trading Down 0.3 % Shares of NYSE PSN opened at $99.05 on Friday. Parsons Co. has a 12-month low of $61.10 and a 12-month high of $114.68. The company has a market cap of $10.52 billion, a price-to-earnings ratio of 150.06, a price-to-earnings-growth ratio of 1.77 and a beta of 0.80. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47. The stock’s 50 day simple moving average is $104.86 and its 200 day simple moving average is $90.77. Parsons ( NYSE:PSN – Get Free Report ) last posted its earnings results on Wednesday, October 30th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.07. The company had revenue of $1.81 billion for the quarter, compared to analysts’ expectations of $1.63 billion. Parsons had a return on equity of 12.74% and a net margin of 1.21%. Equities research analysts expect that Parsons Co. will post 3.02 EPS for the current year. About Parsons ( Free Report ) Parsons Corporation provides integrated solutions and services in the defense, intelligence, and critical infrastructure markets in North America, the Middle East, and internationally. The company operates through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment provides critical technologies, such as cybersecurity; missile defense; intelligence; space launch and ground systems; space and weapon system resiliency; geospatial intelligence; signals intelligence; environmental remediation; border security, critical infrastructure protection; counter unmanned air systems; biometrics and bio surveillance solutions to U.S. Featured Stories Receive News & Ratings for Parsons Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parsons and related companies with MarketBeat.com's FREE daily email newsletter .
Republican Leader Rips Democrats On Credit Ratings Downgrades For Utilities( MENAFN - GetNews) Tianjin YR Chemspec technology Co., Ltd. has recently unveiled its latest product, Hydroxyphenyl Propamidobenzoic Acid (HPPA) , a high-purity compound that is set to make waves in the cosmetic ingredient market. Known for its exceptional skin-soothing , anti-aging, and antioxidant properties, HPPA represents a significant advancement in skincare technology. With a production capacity of 10 tons per year, the company is well-equipped to meet the rising demand for innovative skincare solutions, HPPA is designed specifically to enhance moisture retention and promote overall skin health. As interest in advanced skincare formulations continues to grow, this new compound positions Tianjin YR Chemspec as a key player in the industry. The emphasis on quality is evident, as the company operates an ISO-certified facility that adheres to stringent manufacturing standards. This commitment to excellence ensures that customers can trust the quality and safety of the products they receive. In addition to its robust production capabilities and commitment to quality, Tianjin YR Chemspec distinguishes itself by offering sample support for potential buyers. This initiative demonstrates the company's confidence in HPPA's efficacy and safety, allowing customers to trial the product before making a larger commitment. The ability to test new ingredients is crucial for cosmetic formulators who seek to innovate and improve their product offerings, YR Chemspec® has built a strong reputation as a qualified manufacturer and supplier in the industry. The company has undergone comprehensive audits and received approvals from esteemed organizations such as SGS and ISO. This recognition underscores the company's dedication to quality control and product integrity, which are vital for success in the competitive cosmetics market HPPA, Tianjin YR Chemspec is involved in a variety of industry-university-research collaborative projects. The company is actively working on developing Vitamin Derivatives , Fermented Actives , Plant Extracts, PVP Polymers, and Polyquaternium series products. These initiatives highlight the company's focus on innovation and commitment to incorporating cutting-edge research and technology into their product lines. As the skincare industry continues to evolve, the introduction of HPPA is timely and relevant are increasingly looking for active ingredients that offer tangible benefits, and HPPA's capabilities in soothing the skin, fighting signs of aging, and providing antioxidant protection position it as an attractive option for formulators aiming to create effective skincare products. The global shift towards cleaner, more effective ingredients in cosmetics is also part of the backdrop against which HPPA is being launched. As consumers become more ingredient-savvy, they are increasingly interested in the scientific backing of the products they use. The company's efforts in enhancing moisture retention and improving skin health with HPPA respond directly to consumer demands for nourishing skincare solutions that deliver results. As weather changes and environmental stressors impact skin health, products containing HPPA could provide consumers with the reassurance they seek in their daily skincare rituals significance of this product launch cannot be overstated for those in the cosmetic industry. With skincare being a rapidly evolving field influenced by science, technology, and consumer preference, products like HPPA serve as vital components for brands aiming to deliver efficacy in their formulations, By providing tangible benefits and meeting consumer expectations, HPPA has the potential to secure a prominent position in skincare lines developed by various brands. This places Tianjin YR Chemspec at the forefront of the market, equipped not only with a high-quality ingredient but also with the expertise and certifications that reflect industry standards, As Tianjin YR Chemspec continues to innovate and expand its product offerings, the company's focus on quality, research, and customer service sets a strong foundation for future success. The introduction of HPPA is not just a product launch; it is a strategic move that reinforces the company's commitment to excellence and its role as a significant contributor in the cosmetic ingredient sector MENAFN19122024003238003268ID1109014552 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
LeBron James Vs. NFL: NBA Star Declares Christmas 'Our Day,' But 2024 Ratings DisagreeFarage: Badenoch must apologise for ‘crazy conspiracy theory’ on Reform numbers
On November 18, 2024, GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota. This agreement entails the University sponsoring an Investigational New Drug application for IND 165546 GTB-3650, a Research Program, and serving as a sponsor investigator for a phase 1 clinical trial titled, “GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML.” The Research Program, intended for clinical research use, will have a budget of up to approximately $2 million over three years, funded by GT Biopharma. While University will own the Study data, GT Biopharma can utilize the data subject to compliance with informed consent documents, authorization forms, applicable laws, and terms of the Agreement. Both parties will have the right to publish the Study results. The description of the Agreement provided is not exhaustive, and for full details, readers are directed to the complete text of the Agreement attached to the Current Report on Form 8-K as Exhibit 10.1. In accordance with Item 9.01 of the filing, the company has also disclosed that relevant financial statements and Exhibits are available for reference, with Exhibit 10.1 being the Investigator Initiated Clinical Trial Agreement between GT Biopharma, Inc. and the Regents of the University of Minnesota. The signing of the report on behalf of GT Biopharma, Inc. was done by Alan Urban, the Chief Financial Officer, as per the requirements of the Securities Exchange Act of 1934. This press release conveys actual information from the 8-K filed with the SEC and does not contain any fabricated details or speculative content. This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GT Biopharma’s 8K filing here . GT Biopharma Company Profile ( Get Free Report ) GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. Recommended Stories
Ruben Amorim impressed with Arsenal’s corners after first defeat as Man Utd bossHayleys Energynet has entered into an exclusive strategic partnership with Hengyang Ritar Power Co., Ltd, a global leader with 20+ years of experience in advanced energy storage technology. A subsidiary of Hayleys Fentons Limited, Hayleys Energynet has firmly established itself as a leading provider of UPS and power solutions in Sri Lanka, backed by over 35 years of industry expertise. Hengyang Ritar Power Co., Ltd, a leading energy storage solutions provider, operates eight strategically located production facilities across China and Vietnam, supported by 11 international storage and logistics centres, ensuring efficient global distribution and service. This strategic collaboration aims to revolutionise Sri Lanka’s energy sector by delivering innovative, sustainable and advanced energy solutions tailored to meet the country’s growing energy needs. Together, the two companies will provide high-performance energy storage systems, with battery capacities ranging from 12V/7Ah to 200Ah. Energynet’s product portfolio has been expanded to include advanced lithium batteries and inverters, complementing its existing UPS and battery systems. Hayleys Fentons Limited Managing Director Hasith Prematillake stated; “The partnership between Hayleys Energynet and Hengyang Ritar Power represents a significant milestone in our mission to revolutionise Sri Lanka’s energy landscape. As we combine our global expertise with local innovation, we are not only meeting the growing demand for sustainable energy but also contributing to the nation’s environmental and economic goals through the accelerated adoption of renewable energy. This collaboration will pave the way for a more resilient and energy-secure future, benefiting businesses, consumers, and the country as a whole.” Hayleys Energynet General Manager Mahesh Abeywickrama said; “This partnership strengthens our product portfolio and enables us to offer reliable and sustainable energy solutions through our UPS and power systems, effectively meeting the needs of our customers. We look forward to playing a key role in enhancing the country’s energy infrastructure and supporting Sri Lanka’s renewable energy transition.”
Empowered Funds LLC Increases Holdings in Donnelley Financial Solutions, Inc. (NYSE:DFIN)Quest Partners LLC Decreases Stock Position in Garrett Motion Inc. (NYSE:GTX)
Godaddy chief accounting officer sells $151,409 in stock